Eikon Therapeutics vs Tempus

Side-by-side comparison of AI visibility scores, market position, and capabilities

Tempus leads in AI visibility (74 vs 54)
Eikon Therapeutics logo

Eikon Therapeutics

ChallengerBioTech

Single-Molecule Drug Discovery

Raised $381M IPO on Nasdaq (Feb 2026, EIKN). Proprietary RESOLFT super-resolution microscopy tracks single protein molecules in living cells. Creates new drug discovery data category.

AI VisibilityBeta
Overall Score
C54
Category Rank
#43 of 198
AI Consensus
72%
Trend
stable
Per Platform
ChatGPT
48
Perplexity
49
Gemini
56

About

Eikon Therapeutics is a drug discovery company that went public on Nasdaq in February 2026 (ticker: EIKN) with a $381 million IPO, armed with a proprietary RESOLFT super-resolution microscopy platform that tracks individual protein molecules in living cells in real time. Unlike computational drug discovery approaches that model proteins in isolation, Eikon's platform observes how proteins actually behave within the complex, dynamic environment of living cells — generating a new category of drug discovery data that no other method can produce.

Full profile
Tempus logo

Tempus

LeaderLife Sciences & BioTech

AI-Enabled Precision Medicine

Publicly traded AI precision medicine company (Nasdaq: TEM); $1.27B revenue in 2025 (+83% YoY); $14B+ market cap; genomic profiling, algorithmic diagnostics, and clinical trial matching across oncology, neurology, and cardiology.

AI VisibilityBeta
Overall Score
B74
Category Rank
#11 of 198
AI Consensus
68%
Trend
stable
Per Platform
ChatGPT
71
Perplexity
68
Gemini
80

About

Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder of Groupon) and headquartered in Chicago, Illinois, Tempus built the world's largest library of clinical and molecular data and applies AI to help physicians make more personalized, data-driven treatment decisions. The company's core offerings include genomic profiling (sequencing tumor DNA to identify mutations and actionable targets), algorithmic diagnostic tests (AI-driven companion diagnostics for cancer treatment selection), clinical trial matching (connecting eligible patients to appropriate studies), and data licensing to pharmaceutical and biotech partners for drug discovery and clinical development.

Full profile

AI Visibility Head-to-Head

54
Overall Score
74
#43
Category Rank
#11
72
AI Consensus
68
stable
Trend
stable
48
ChatGPT
71
49
Perplexity
68
56
Gemini
80
52
Claude
77
59
Grok
69

Key Details

Category
Single-Molecule Drug Discovery
AI-Enabled Precision Medicine
Tier
Challenger
Leader
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Eikon Therapeutics
Single-Molecule Drug Discovery

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.